LisaTaliadoros

Partner

(T) + 61.3.9101.6821

Head of the Intellectual Property Practice in Australia, Lisa Taliadoros has nearly 20 years of experience in high-value IP disputes, including in relation to patents, copyrights, and trademarks.

A focus of Lisa's practice is complex, multijurisdictional patent litigation in the Federal Court of Australia. She has acted across a range of industries, including pharmaceuticals, life sciences, biotechnology, mining, and building and construction. Lisa has acted in the High Court of Australia in two recent landmark decisions concerning the scope of patent protection for Myriad's BRA1 (breast cancer) patents and Sanofi's leflunomide patent for the treatment of skin disorders and arthritic conditions. In addition, she has acted in the Federal Court of Australia for other large multinational pharmaceutical companies in matters relating to patents for new compounds, biologics, biosimilars, drug formulations, drug delivery devices, dental technology, and methods of treatment. She also has acted in matters concerning patents relating to mining tools and technologies (including deep water drilling apparatus) and building systems.

Lisa is a member of the Intellectual Property Law Subcommittee of the Law Council of Victoria.

Prior to obtaining her law degree, Lisa was a scientist at two of Australia's preeminent research organizations, the CSIRO and the Centenary Institute of Cell Biology and Cancer Medicine. Her research projects involved the development of vaccines for avian infectious bronchitis virus and investigating the role of lymphotoxin alpha in the pathogenesis of autoimmune disorders.

Lisa serves as Jones Day's diversity partner for Australia.

Experience

  • Sanofi challenges Amgen's patent applications for anti-PCSK9 antibodies before Australian Patent OfficeJones Day is acting in an opposition proceeding for Sanofi and Regeneron in relation to their challenge to a portfolio of applications held by Amgen Inc. that claim anti-PCSK9 antibodies and their use in the treatment of hypercholesterolemia.
  • Myriad acts in High Court's first consideration of genetic material patentsJones Day acted for Myriad Genetics, Inc. in a landmark Australian case before the High Court of Australia.
  • ToolGen defends revolutionary CRISPR technology patentJones Day is acting for ToolGen, Inc. in relation to a challenge to its patent rights concerning CRISPR, a technology that has revolutionized the field of molecular biology including gene editing in the medical, biotechnology, and agricultural and farming industries.
  • Bradken successfully defends patent infringement case brought by CQMS concerning mining equipmentJones Day acted for Bradken Limited in its successful defense against claims made by CQMS Pty Ltd that Bradken infringed patents concerning ground engaging tools.
  • Idenix asserts patent infringement against Gilead in Australia related to Sovaldi® and Harvoni®Jones Day represents Idenix Pharmaceuticals LLC (a subsidiary of Merck & Co., Inc.) in patent litigation against Gilead in the Federal Court of Australia over sofosbuvir, the active ingredient in Sovaldi® and Harvoni®, Gilead's blockbuster drugs for treating Hepatitis C.
  • We use cookies to deliver our online services. Details of the cookies and other tracking technologies we use and instructions on how to disable them are set out in our Cookies Policy. By using this website you consent to our use of cookies.